Drug Safety Communication Alert

Drug Safety Communication Alert

May 19, 2016 | Pharmaceutical Litigation

Napoli Shkolnik PLLC has learned that the Federal Drug Administration (FDA) has issued an alert for the patients of diabetes drugs Invokana and Invokamet.

As part of ongoing clinical trials, the interim safety results have found an increase in leg and foot amputations, mostly affecting the toes, in patients being treated with the diabetes medication Invokana and Invokamet.

In addition, users of these diabetes drugs have also experienced other serious side effects such as kidney failure, heart attack and the health condition known as ketoacidosis, which causes diabetic comas or death. Current lawsuits allege that the manufacturer failed to properly warn patients of the potential increased risks associated with taking Invokana and Invokamet.

These possible health risks are obviously serious and we encourage patients of these adult type II diabetes drugs to contact us immediately if they are experiencing the above described complications.

Drug Safety Communication Alert
Rate this post

Share This:
CATEGORY: Pharmaceutical Litigation

GET HELP NOW